The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Effects of the Converting Enzyme Inhibitor Quinapril (CI‐906) on Blood Pressure, Renin‐Angiotensin System, and Prostanoids in Essential Hypertension
Fourteen patients with mild to moderate essential hypertension were r and omized , after a baseline placebo period of 4 weeks , to receive the angiotensin converting enzyme ( ACE ) inhibitor quinapril or a placebo . During a 12 week , double-blind phase , the dosage of quinapril was increased from 10 to 40 mg twice daily being doubled every 4 weeks . At the end of the baseline period and of each month of the double-blind phase , 12 h overnight urine collection s were made and morning blood sample s were taken about 12 h after the last dose of medication . During the double-blind phase , blood pressure in the  quinapril  group ( n = 7 ) decreased from 159 ± 3/105 ± 1 to 141 ± 6/94 ± 2 mm Hg ( mean ± SEM ) . Serum ACE activity and plasma angiotensin II concentration were reduced to 4 ± 1 % and 14 ± 1 % of the pretreatment values , respectively . Neither the plasma concentrations nor the urinary excretions of prostagl and in E2 , 6-keto-prostagl and in F1α ( a prostacyclin metabolite ) , or thromboxane B2 ( a metabolite of thromboxane A2 ) were affected by quinapril . In the placebo group , blood pressure tended to decline but the biochemical variables remained essentially unchanged . These results indicate that prostanoids are not involved in the antihypertensive action of quinapril , the principal effect of which seems to be inhibition of the renin-angiotensin system
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .